Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria

Malaria Clinical Trial

Official title: An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan

Status Completed

Clinical Trial Summary

To determine whether two cheap antifolates (chlorproguanil-dapsone and sulfadoxine-pyrimethamine) which work against falciparum malaria in this region are sufficiently effective against vivax malaria to be deployed in areas where diagnosis is poor and the burden of malaria is high, a randomised controlled trial of the three drugs is being undertaken comparing their efficacy in treating malaria.

Clinical Trial Description

Objectives:

Primary:

To evaluate the comparative efficacy of chlorproguanil / dapsone with sulfadoxine-pyrimethamine for the treatment of vivax malaria in Pakistan and eastern Afghanistan.

Secondary:

• To compare the efficacy of chlorproguanil-dapsone and sulfadoxine-pyrimethamine with chloroquine

• To evaluate the safety profile of chlorproguanil / dapsone in south Asians from this region when used for the treatment of vivax malaria.

• To evaluate the effect of chlorproguanil / dapsone on gametocyte clearance rates.

• To evaluate the effect of chlorproguanil / dapsone on subsequent relapse due to vivax malaria.

Study Population:

750 P.vivax positive individuals recruited from the Malaria Reference Centre in Jalalabad, Afghanistan and at health facilities in Afghan refugee camps in North West Frontier Province (NWFP), Pakistan supervised by HealthNet International

Efficacy Parameters :

Primary Efficacy Variable:

• Day 14 slide clearance rate (complete clearance of parasites), assessed by microscopists who are blind to treatment allocation. Slides will be double read.

Secondary Efficacy Variables

• Day 28 slide clearance rate defined as the number of treated patients with clearance of parasitaemia within 14 days of starting treatment, without subsequent recrudescence up to day 28.

• Day 14 clinical failure rate (presence of symptoms of malaria in the presence of parasitaemia).

• Day 28 clinical failure rate.

• Adverse events.

• Haemoglobin level increased by at least 1g/dl by day 14.

• Clearance of gametocytaemia by day 3, 7, and 14.

• Number of subsequent malaria episodes in next 6 months. It is assumed that the population of each treatment arm is equally likely to be re-infected in this time scale. Therefore any measurable difference in number of subsequent episodes between treatment arms will be due to a relapse.

• In G6PD deficient patients the change in mean haemoglobin.

Safety Parameters:

Adverse events and laboratory findings will be monitored in all patients. Regular haemoglobin to identify haemolysis.

Study design:

Recruitment and administration:

Recruitment and administration of all treatments will be directly observed by the trial coordinator and trial pharmacist, and/or health unit clinician.

Dosing Schedules:

Chlorproguanil-dapsone (Lapdap): (target doses 2.0 and 2.5 mg/kg respectively) daily for 3 days .

Sulfadoxine - pyrimethamine (SP): (target doses 1.25 and 25.0 mg/kg respectively) once only.

Chloroquine (CQ): (target dose 25mg/kg ) daily for 3 days.

Follow up:

Patients will return to the clinic on days 0, 1, 2, 3, 7, 14, 21 and 28 for supervised dosing, thick and thin smears, blood spot filter papers, update of clinical record forms, determination of haemoglobin, full blood cell counts, liver function tests, determination of adverse events and concomitant medication details, as appropriate. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Malaria
• Malaria, Vivax
• Vivax Malaria

• NCT number: NCT00158561
• Study type: Interventional
• Source: London School of Hygiene and Tropical Medicine
• Status: Completed
• Phase: Phase 3
• Start date: February 2004
• Completion date: March 2006